Antiurolithic activity of Origanum vulgare is mediated through multiple pathways

BMC Complementary and Alternative Medicine

Volumn 11, Issue , 2011, Pages

  Khan, Aslam ^a,b,c   Bashir, Samra ^b   Khan, Saeed R ^c   Gilani, Anwar H ^b,d  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b AGA KHAN UNIVERSITY MEDICAL COLLEGE   (Pakistan)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM CHLORIDE; ANTIUROLITHIASIS AGENT; CALCIUM OXALATE; CREATININE; ETHYLENE GLYCOL; HYDROCHLOROTHIAZIDE; LACTATE DEHYDROGENASE; ORIGANUM VULGARE EXTRACT; PLANT EXTRACT; UNCLASSIFIED DRUG; UREA; VERAPAMIL; ANTIOXIDANT; DIURETIC AGENT; FREE RADICAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLADDER; CELL SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRYSTALLURIA; CYTOTOXICITY; DRUG DOSE INCREASE; DRUG MECHANISM; ENZYME RELEASE; EPITHELIUM CELL; HYPEROXALURIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; KIDNEY PARENCHYMA; LIPID PEROXIDATION; MALE; NONHUMAN; OREGANO; POLYURIA; PROTEIN SECRETION; RABBIT; RAT; UREA BLOOD LEVEL; UROLITHIASIS; WEIGHT REDUCTION; ANIMAL; CELL LINE; CHEMISTRY; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; ORIGANUM; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; CALCIUM OXALATE; CELL LINE; DIURETICS; FEMALE; FREE RADICALS; HUMANS; LIPID PEROXIDATION; MALE; ORIGANUM; PLANT EXTRACTS; RABBITS; RATS; RATS, WISTAR; UROLITHIASIS;

EID: 80054052935     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-11-96     Document Type: Article

References (79)

1. Lopez M, Hoppe B. History, epidemiology and regional diversities of urolithiasis. Pediatr Nephrol 2008,
2. Coe FL, Keck J, Norton ER. The natural history of calcium urolithiasis. JAMA 1977, 238(14):1519-1523. 10.1001/jama.238.14.1519, 578220.
3. Bashir S, Gilani AH, Siddiqui AA, Pervez S, Khan SR, Sarfaraz NJ, Shah AJ. Berberis vulgaris root bark extract prevents hyperoxaluria induced urolithiasis in rats. Phytother Res 2010, 24(8):1250-1255.
4. Pak CY. Kidney stones. Lancet 1998, 351(9118):1797-1801. 10.1016/S0140-6736(98)01295-1, 9635968.
5. Moe OW. Kidney stones: pathophysiology and medical management. Lancet 2006, 367(9507):333-344. 10.1016/S0140-6736(06)68071-9, 16443041.
6. Grover PK, Kim DS, Ryall RL. The effect of seed crystals of hydroxyapatite and brushite on the crystallization of calcium oxalate in undiluted human urine in vitro: implications for urinary stone pathogenesis. Mol Med 2002, 8(4):200-209. 2039983, 12149569.
7. Srisubat A, Potisat S, Lojanapiwat B, Setthawong V, Laopaiboon M. Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones. Cochrane Database Syst Rev 2009, (4):CD007044.
8. Butterweck V, Khan SR. Herbal medicines in the management of urolithiasis: alternative or complementary?. Planta Med 2009, 75(10):1095-1103. 10.1055/s-0029-1185719, 19444769.
9. Gurocak S, Kupeli B. Consumption of historical and current phytotherapeutic agents for urolithiasis: a critical review. J Urol 2006, 176(2):450-455. 10.1016/j.juro.2006.03.034, 16813863.
10. Hess B. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi]. Ther Umsch 2003, 60(2):79-87. 10.1024/0040-5930.60.2.79, 12649986.
11. Mattle D, Hess B. Preventive treatment of nephrolithiasis with alkali citrate--a critical review. Urol Res 2005, 33(2):73-79. 10.1007/s00240-005-0464-8, 15875173.
12. Gilani AH, Rahman AU. Trends in ethnopharmocology. J Ethnopharmacol 2005, 100(1-2):43-49. 10.1016/j.jep.2005.06.001, 16127805.
13. Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine 2001, 8(5):401-409. 10.1078/0944-7113-00060, 11695885.
14. Fleming T. PDR for herbal medicines. 1998, Medical Economics Company, First.
15. Baquar SR. Medicinal and Poisonous Plants of Pakistan. 1989, Karachi: Printas.
16. Usmanghani K, Saeed A, Alam MT. Indusyunic Medicine. 1997, Karachi: University of Karachi Press.
17. Duke JA. Handbook of medicinal herbs. 2002, Boca Raton, LA: CRC Press.
18. National Research Council, Guide for the care and use of laboratory animals. 1996, Washington, DC: National Academy Press.
19. Williamson EM, Okpako DT, Evans FJ. Pharmacological methods in phytotherapy research: Selection, Preparation and Pharmacological Evaluation of Plant Material v.1. 1996, Chichester: John Wiley & Sons.
20. Gilani AH, Mandukhail SU, Iqbal J, Yasinzai M, Aziz N, Khan A, Rehman NU. Antispasmodic and vasodilator activities of Morinda citrifolia root extract are mediated through blockade of voltage dependent calcium channels. BMC Complement Altern Med 2010, 10(1):2. 10.1186/1472-6882-10-2, 2829485, 20070879.
21. Gilani AH, Khan A, Khan AU, Bashir S, Rehman NU, Mandukhail SU. Pharmacological basis for the medicinal use of Holarrhena antidysenterica in gut motility disorders. Pharm Biol 2010, 48(11):1240-1246. 10.3109/13880201003727960, 20822397.
22. Edeoga HO, Okwu DE, Mbaebie BO. Phytochemical constituents of some Nigerian medicinal plants. Afr J Biotechnol 2005, 4(7):685-688.
23. Hess B, Meinhardt U, Zipperle L, Giovanoli R, Jaeger P. Simultaneous measurements of calcium oxalate crystal nucleation and aggregation: impact of various modifiers. Urol Res 1995, 23(4):231-238. 10.1007/BF00393304, 8533209.
24. Ebisuno S, Komura T, Yamagiwa K, Ohkawa T. Urease-induced crystallizations of calcium phosphate and magnesium ammonium phosphate in synthetic urine and human urine. Urol Res 1997, 25(4):263-267. 10.1007/BF00942096, 9286035.
25. Guerra A, Meschi T, Allegri F, Schianchi T, Adorni G, Novarini A, Borghi L. Calcium oxalate crystallization in untreated urine, centrifuged and filtered urine and ultrafiltered urine. Clin Chem Lab Med 2004, 42(1):45-50. 10.1515/CCLM.2004.009, 15061379.
26. Huang DJ, Chen HJ, Hou WC, Lin CD, Lin YH. Active recombinant thioredoxin h protein with antioxidant activities from sweet potato (Ipomoea batatas [L.] Lam Tainong 57) storage roots. J Agric Food Chem 2004, 52(15):4720-4724. 10.1021/jf0498618, 15264905.
27. Ajith TA, Usha S, Nivitha V. Ascorbic acid and [alpha]-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study. Clin Chim Acta 2007, 375(1-2):82-86. 10.1016/j.cca.2006.06.011, 16889761.
28. Borchert VE, Czyborra P, Fetscher C, Goepel M, Michel MC. Extracts from Rhois aromatica and Solidaginis virgaurea inhibit rat and human bladder contraction. Naunyn Schmiedebergs Arch Pharmacol 2004, 369(3):281-286. 10.1007/s00210-004-0869-x, 14963639.
29. Farre AJ, Colombo M, Fort M, Gutierrez B. Differential effects of various Ca2+ antagonists. Gen Pharmacol 1991, 22(1):177-181. 10.1016/0306-3623(91)90331-Y, 1904831.
30. Van Rossum JM. Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther 1963, 143:299-330.
31. Consolini AE, Baldini OA, Amat AG. Pharmacological basis for the empirical use of Eugenia uniflora L. (Myrtaceae) as antihypertensive. J Ethnopharmacol 1999, 66(1):33-39. 10.1016/S0378-8741(98)00194-9, 10432205.
32. Atmani F, Slimani Y, Mimouni M, Hacht B. Prophylaxis of calcium oxalate stones by Herniaria hirsuta on experimentally induced nephrolithiasis in rats. BJU Int 2003, 92(1):137-140. 10.1046/j.1464-410X.2003.04289.x, 12823398.
33. Bashir S, Gilani AH. Antiurolithic effect of berberine is mediated through multiple pathways. Eur J Pharmacol 651(1-3):168-175.
34. Lemhadri A, Zeggwagh NA, Maghrani M, Jouad H, Eddouks M. Anti-hyperglycaemic activity of the aqueous extract of Origanum vulgare growing wild in Tafilalet region. J Ethnopharmacol 2004, 92(2-3):251-256. 10.1016/j.jep.2004.02.026, 15138008.
35. Srihari T, Sengottuvelan M, Nalini N. Dose-dependent effect of oregano (Origanum vulgare L.) on lipid peroxidation and antioxidant status in 1,2-dimethylhydrazine-induced rat colon carcinogenesis. J Pharm Pharmacol 2008, 60(6):787-794.
36. Pizzolato P. Mercurous nitrate as a histochemical reagent for calcium phosphate in bone and pathological calcification and for calcium oxalate. Histochem J 1971, 3(6):463-469. 10.1007/BF01014785, 4110473.
37. Vanachayangkul P, Chow N, Khan SR, Butterweck V. Prevention of renal crystal deposition by an extract of Ammi visnaga L. and its constituents khellin and visnagin in hyperoxaluric rats. Urol Res 2010,
38. Daly JA, Ertingshausen G. Direct method for determining inorganic phosphate in serum with the "CentrifiChem". Clin Chem 1972, 18(3):263-265.
39. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193(1):265-275.
40. Tiselius HG. Epidemiology and medical management of stone disease. BJU Int 2003, 91(8):758-767. 10.1046/j.1464-410X.2003.04208.x, 12709088.
41. Guerra A, Meschi T, Allegri F, Prati B, Nouvenne A, Fiaccadori E, Borghi L. Concentrated urine and diluted urine: the effects of citrate and magnesium on the crystallization of calcium oxalate induced in vitro by an oxalate load. Urol Res 2006, 34(6):359-364. 10.1007/s00240-006-0067-z, 16953377.
42. Wesson JA, Worcester EM, Wiessner JH, Mandel NS, Kleinman JG. Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney international 1998, 53(4):952-957. 10.1111/j.1523-1755.1998.00839.x, 9551403.
43. Wesson JA, Ward MD. Role of crystal surface adhesion in kidney stone disease. Curr Opin Nephrol Hypertens 2006, 15(4):386-393. 10.1097/01.mnh.0000232879.50716.6f, 16775453.
44. Wang AY. Vascular and other tissue calcification in peritoneal dialysis patients. Perit Dial Int 2009, 29(Suppl 2):S9-S14.
45. Khan SR. Animal models of kidney stone formation: an analysis. World J Urol 1997, 15(4):236-243. 10.1007/BF01367661, 9280052.
46. Marangella M, Bagnis C, Bruno M, Vitale C, Petrarulo M, Ramello A. Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis. Urol Int 2004, 72(Suppl 1):6-10.
47. Carvalho M, Vieira MA. Changes in calcium oxalate crystal morphology as a function of supersaturation. Int Braz J Urol 2004, 30(3):205-208. discussion 209.
48. Kato Y, Yamaguchi S, Yachiku S, Nakazono S, Hori J, Wada N, Hou K. Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis. Urology 2004, 63(1):7-11. discussion 11-12, 10.1016/j.urology.2003.09.057, 14751336.
49. Aihara K, Byer KJ, Khan SR. Calcium phosphate-induced renal epithelial injury and stone formation: involvement of reactive oxygen species. Kidney Int 2003, 64(4):1283-1291. 10.1046/j.1523-1755.2003.00226.x, 12969146.
50. Escobar C, Byer KJ, Khaskheli H, Khan SR. Apatite induced renal epithelial injury: insight into the pathogenesis of kidney stones. J Urol 2008, 180(1):379-387. 10.1016/j.juro.2008.02.041, 2693724, 18499159.
51. Byer K, Khan SR. Citrate provides protection against oxalate and calcium oxalate crystal induced oxidative damage to renal epithelium. J Urol 2005, 173(2):640-646. 10.1097/01.ju.0000143190.49888.c7, 15643280.
52. Santhosh Kumar M, Selvam R. Supplementation of vitamin E and selenium prevents hyperoxaluria in experimental urolithic rats. J Nutr Biochem 2003, 14(6):306-313. 10.1016/S0955-2863(03)00033-0, 12873711.
53. Thamilselvan S, Khan SR, Menon M. Oxalate and calcium oxalate mediated free radical toxicity in renal epithelial cells: effect of antioxidants. Urol Res 2003, 31(1):3-9.
54. Babich H. Butylated hydroxytoluene (BHT): A review. Environ Res 1982, 29(1):1-29. 10.1016/0013-9351(82)90002-0, 6754366.
55. Lin SP, Tsai SY, Lin YL, Kuo SC, Hou YC, Chao PD. Biotransformation and pharmacokinetics of 4-(3,4-dihydroxybenzoyloxymethyl)phenyl-O-beta-D-glucopyranoside, an antioxidant isolated from Origanum vulgare. J AgricFood Chem 2008, 56(8):2852-2856.
56. Matsuura H, Chiji H, Asakawa C, Amano M, Yoshihara T, Mizutani J. DPPH radical scavengers from dried leaves of oregano (Origanum vulgare). Biosci Biotechnol Biochem 2003, 67(11):2311-2316. 10.1271/bbb.67.2311, 14646188.
57. Fernandez-Cruz E, Escartin P, Bootello A, Kreisler M, Segovia de Arana JM. Hepatocyte damage induced by lymphocytes from patients with chronic liver diseases, as detected by LDH release. Clin Exp Immunol 1978, 31(3):436-442. 1541248, 657588.
58. Ohgaki K, Horiuchi K, Hikima N, Kondo Y. Facilitation of expulsion of ureteral stones by addition of alpha1-blockers to conservative therapy. Scand J Urol Nephrol 2010, 44(6):420-424. 10.3109/00365599.2010.497769, 20604720.
59. Seitz C, Liatsikos E, Porpiglia F, Tiselius HG, Zwergel U. Medical therapy to facilitate the passage of stones: what is the evidence?. Eur Urol 2009, 56(3):455-471. 10.1016/j.eururo.2009.06.012, 19560860.
60. Bolton TB. Mechanisms of action of transmitters and other substances on smooth muscle. Physiol Rev 1979, 59(3):606-718.
61. Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol Rev 1986, 38(4):321-416.
62. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. Goodman and Gilman's manual of pharmacology and therapeutics 2006, 183-200. New Yark: McGraw-Hill, 11.
63. Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annual Review PharmacolToxicol 1977, 17(1):149-166.
64. Dasaeva LA, Shilov EM, Shatokhina SN. [Diuress for the treatment of early stages of urolithiasis]. Klin Med (Mosk) 2003, 81(10):50-52.
65. Goldfarb DS, Coe FL. In A.M. Davison, J.S. Cameron, E. Ritz, J. Grünfeld, C.G. Winearls, C. Ponticelli & C.V. The medical management of stone disease. Oxford textbook of clinical nephrology 2005, 1199-1279. New Yark: Oxford University Press.
66. Tsai CH, Chen YC, Chen LD, Pan TC, Ho CY, Lai MT, Tsai FJ, Chen WC. A traditional Chinese herbal antilithic formula, Wulingsan, effectively prevents the renal deposition of calcium oxalate crystal in ethylene glycol-fed rats. Urol Res 2008, 36(1):17-24. 10.1007/s00240-007-0122-4, 18040675.
67. Divakar K, Pawar AT, Chandrasekhar SB, Dighe SB, Divakar G. Protective effect of the hydro-alcoholic extract of Rubia cordifolia roots against ethylene glycol induced urolithiasis in rats. Food Chem Toxicol 48(4):1013-1018.
68. Bashir S, Gilani AH. Antiurolithic effect of berberine is mediated through multiple pathways. Eur J Pharmacol 2011, 651(1-3):168-175. 10.1016/j.ejphar.2010.10.076, 21114977.
69. Li Y, McMartin KE. Strain differences in urinary factors that promote calcium oxalate crystal formation in the kidneys of ethylene glycol-treated rats. Am J Physiol Renal Physiol 2009, 296(5):F1080-1087. 10.1152/ajprenal.90727.2008, 19244400.
70. Fan J, Glass MA, Chandhoke PS. Impact of ammonium chloride administration on a rat ethylene glycol urolithiasis model. Scanning Microsc 1999, 13(2-3):299-306.
71. Park HK, Jeong BC, Sung MK, Park MY, Choi EY, Kim BS, Kim HH, Kim JI. Reduction of oxidative stress in cultured renal tubular cells and preventive effects on renal stone formation by the bioflavonoid quercetin. J Urol 2008, 179(4):1620-1626. 10.1016/j.juro.2007.11.039, 18295251.
72. Santhosh Kumar M, Selvam R. Supplementation of vitamin E and selenium prevents hyperoxaluria in experimental urolithic rats. JNut Biochem 2003, 14(6):306-313.
73. Wiessner JH, Hasegawa AT, Hung LY, Mandel GS, Mandel NS. Mechanisms of calcium oxalate crystal attachment to injured renal collecting duct cells. Kidney Int 2001, 59(2):637-644. 10.1046/j.1523-1755.2001.059002637.x, 11168945.
74. Revuelta MP, Cantabrana B, Hidalgo A. Depolarization-dependent effect of flavonoids in rat uterine smooth muscle contraction elicited by CaCl2. Gen Pharmacol 1997, 29(5):847-857. 10.1016/S0306-3623(97)00002-5, 9347337.
75. Pietta P. Flavonoids in medicinal plants. Flavonoids in Health and Disease 1998, 61-110. New York: Marcel Dekker, Rive-Evans CV, Packer L.
76. Pietta PG. Flavonoids as antioxidants. J Nat Prod 2000, 63(7):1035-1042. 10.1021/np9904509, 10924197.
77. Ramamoorthy J, Venkataraman S, Meera R, Chiristina AJM, Chidambaranathan N. Physio-Phytochemical screening and Diuretic activity of leaves of Pavetta indica Linn. J Pharm Sci Res 2010, 2(8):506-512.
78. Ocana-Fuentes A, Arranz-Gutierrez E, Senorans FJ, Reglero G. Supercritical fluid extraction of oregano (Origanum vulgare) essentials oils: anti-inflammatory properties based on cytokine response on THP-1 macrophages. Food Chem Toxicol 2010, 48(6):1568-1575. 10.1016/j.fct.2010.03.026, 20332013.
79. Sarac N, Ugur A. Antimicrobial activities of the essential oils of Origanum onites L., Origanum vulgare L. subspecies hirtum (Link) Ietswaart, Satureja thymbra L., and Thymus cilicicus Boiss. & Bal. growing wild in Turkey. J Med Food 2008, 11(3):568-573. 10.1089/jmf.2007.0520, 18800908.